Profile data is unavailable for this security.
About the company
Stella Pharma Corp is a Japan-based company mainly engaged in the therapeutic drug research and development. It is engaged in the research and development of boron drugs for boron neutron capture therapy (BNCT). BNCT is a radiation therapy that selectively destroys cancer cells by utilizing the fission reaction of B-10, which is a stable isotope of boron, and thermal neutrons with low energy. Nucleus of B-10, which is a stable isotope of boron, absorbs low-energy low-speed neutrons and immediately splits into a helium nucleus (4He nucleus (α particle)) and a lithium nuclei (7Li nuclei). When a substance containing B-10 selectively accumulates in cancer cells and is irradiated with thermal neutrons, cancer cells are selectively destroyed. Product includes steboronin (SPM-011). A phase II clinical trial is conducted for brain tumor, head and neck cancer and recurrent malignant glioma. Phase I clinical trial is started for malignant melanoma, a type of skin cancer, and angiosarcoma.
- Revenue in JPY (TTM)968.76m
- Net income in JPY-279.32m
- Incorporated2007
- Employees43.00
- LocationStella Pharma Corp3-2-7, Koraibashi, Chuo-kuOSAKA-SHI 541-0043JapanJPN
- Phone+81 647071516
- Fax+81 647072077
- Websitehttps://stella-pharma.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solasia Pharma KK | 429.00m | -876.00m | 9.02bn | 23.00 | -- | 4.96 | -- | 21.03 | -3.79 | -3.79 | 1.81 | 6.65 | 0.2447 | 1.84 | 2.13 | -- | -49.96 | -64.76 | -58.36 | -79.60 | 48.48 | 58.61 | -204.20 | -297.25 | 5.70 | -61.50 | 0.0514 | -- | 35.76 | -1.13 | 54.87 | -- | -- | -- |
| Symbio Pharmaceuticals Ltd | 1.31bn | -4.78bn | 9.02bn | 108.00 | -- | 6.13 | -- | 6.90 | -95.49 | -95.49 | 26.04 | 21.39 | 0.296 | 1.37 | 3.83 | -- | -108.11 | -19.84 | -140.91 | -24.15 | 72.45 | 74.71 | -365.25 | -26.66 | 2.74 | -44.43 | 0.6092 | -- | -46.69 | -15.23 | -24.59 | -- | -11.15 | -- |
| K Pharma Inc | 0.00 | -993.23m | 10.12bn | 17.00 | -- | 7.99 | -- | -- | -85.59 | -85.59 | 0.00 | 109.00 | 0.00 | 0.00 | -- | -- | -37.53 | -- | -38.74 | -- | -- | -- | -- | -- | 28.29 | -1,982.81 | 0.5424 | -- | -- | -- | -17.34 | -- | -- | -- |
| Wakamoto Pharmaceutical Co Ltd | 9.29bn | 298.60m | 11.78bn | 286.00 | 39.28 | 0.9702 | 15.90 | 1.27 | 8.60 | 8.60 | 267.77 | 348.39 | 0.6006 | 1.62 | 3.06 | 32,493,160.00 | 1.93 | -0.0678 | 2.22 | -0.0781 | 47.70 | 48.65 | 3.21 | -0.1246 | 2.42 | -- | 0.0082 | -- | 0.6595 | -6.53 | -40.86 | -- | 21.87 | -- |
| CellSeed Inc | 83.68m | -1.10bn | 12.54bn | 38.00 | -- | 9.14 | -- | 149.89 | -31.83 | -31.83 | 2.41 | 35.67 | 0.0409 | 0.6561 | 3.81 | -- | -54.00 | -46.88 | -59.08 | -50.95 | 51.09 | 53.64 | -1,319.46 | -593.85 | 5.81 | -- | 0.0949 | -- | -56.71 | -15.95 | -28.41 | -- | 21.04 | -- |
| Immuno-Biological Laboratories Co., Ltd. | 1.03bn | 363.89m | 14.24bn | 58.00 | 39.13 | 8.08 | 37.25 | 13.81 | 39.07 | 39.07 | 110.76 | 189.25 | 0.5456 | 0.8603 | 4.81 | 17,786,030.00 | 19.25 | -4.96 | 22.46 | -5.77 | 70.35 | 62.70 | 35.27 | -11.27 | 3.96 | 2,702.08 | 0.0947 | -- | 18.71 | 10.95 | 33.40 | -- | -- | -- |
| TAIKO PHARMACEUTICAL CO LTD | 6.40bn | 923.00m | 14.94bn | 214.00 | 16.05 | 1.74 | 12.56 | 2.34 | 18.37 | 18.37 | 127.34 | 169.51 | 0.5080 | 1.77 | 2.62 | -- | 7.34 | -18.99 | 9.32 | -24.04 | 54.42 | 40.20 | 14.44 | -46.31 | 2.72 | -- | 0.0874 | -- | 1.67 | -- | 2.78 | -- | -- | -- |
| CanBas Co Ltd (Parent) | 0.00 | -1.25bn | 15.18bn | 14.00 | -- | 6.38 | -- | -- | -64.11 | -64.11 | 0.00 | 120.62 | 0.00 | -- | -- | 0.00 | -44.48 | -57.04 | -46.19 | -62.13 | -- | -- | -- | -4,587.85 | -- | -566.18 | 0.00 | -- | -- | -- | 4.27 | -- | -- | -- |
| Stella Pharma Corp | 968.76m | -279.32m | 16.71bn | 43.00 | -- | 6.20 | -- | 17.25 | -8.21 | -8.21 | 28.47 | 79.22 | 0.1966 | 0.0944 | 2.91 | 22,529,260.00 | -5.67 | -16.41 | -5.96 | -18.19 | 87.88 | 87.03 | -28.83 | -176.16 | 13.81 | -45.69 | 0.226 | -- | 256.62 | -- | 81.56 | -- | -21.34 | -- |
| ReproCell Inc | 2.52bn | -324.61m | 16.97bn | 99.00 | -- | 1.93 | -- | 6.74 | -3.42 | -3.42 | 26.63 | 92.82 | 0.2328 | 4.15 | 5.92 | 25,450,770.00 | -3.00 | -4.09 | -3.63 | -4.47 | 49.35 | 43.75 | -12.88 | -13.66 | 4.93 | -- | 0.00 | -- | 22.74 | 19.94 | 428.65 | -- | -6.31 | -- |
| StemRIM Inc | 0.00 | -1.90bn | 18.55bn | 45.00 | -- | 2.70 | -- | -- | -30.56 | -30.56 | 0.00 | 109.73 | 0.00 | -- | -- | 0.00 | -24.08 | -12.71 | -24.55 | -12.88 | -- | -- | -- | -167.35 | 47.00 | -- | 0.00 | -- | -- | -- | 4.59 | -- | -22.11 | -- |
| Kubota Pharmaceutical Holdings Co Ltd | 21.34m | -676.25m | 19.04bn | 19.00 | -- | 10.50 | -- | 892.51 | -10.91 | -10.91 | 0.3341 | 15.72 | 0.0121 | 3.54 | 7.98 | -- | -38.41 | -44.81 | -42.10 | -49.35 | -14.68 | -- | -3,169.69 | -8,411.59 | 12.49 | -- | 0.0121 | -- | -21.53 | -10.80 | 49.26 | -- | -4.55 | -- |
| Ohki Healthcare Holdings Co Ltd | 359.41bn | 2.43bn | 19.39bn | 648.00 | 7.72 | 0.5657 | 6.85 | 0.054 | 178.43 | 178.43 | 26,346.69 | 2,435.83 | 2.26 | 9.83 | 4.34 | 554,637,400.00 | 1.53 | 1.77 | 6.23 | 7.74 | 5.31 | 5.26 | 0.677 | 0.6977 | 0.8306 | -- | 0.2686 | 14.17 | 4.42 | 4.74 | 19.41 | 2.21 | 45.68 | 6.47 |
| Astena Holdings Co Ltd | 62.74bn | 2.19bn | 20.26bn | 1.54k | 9.09 | 0.7349 | 4.40 | 0.3229 | 54.22 | 54.22 | 1,555.72 | 670.84 | 0.8961 | 3.62 | 2.88 | 40,663,640.00 | 3.11 | 0.9587 | 6.26 | 1.76 | 34.85 | 30.40 | 3.47 | 1.05 | 0.9228 | -- | 0.4519 | 114.25 | 8.19 | -0.808 | 186.60 | 1.97 | 12.61 | 2.38 |
| Fuso Pharmaceutical Industries Ltd | 62.17bn | -4.01bn | 22.92bn | 1.34k | -- | 0.5974 | -- | 0.3687 | -469.00 | -469.00 | 7,280.21 | 4,059.08 | 0.7307 | 3.25 | 2.32 | 46,394,780.00 | -4.71 | 0.7682 | -9.76 | 1.29 | 26.39 | 26.94 | -6.44 | 1.05 | 0.8228 | 69.88 | 0.4617 | 106.29 | 9.31 | 5.25 | -338.78 | -- | 4.37 | 6.45 |
| RaQualia Pharma Inc | 3.98bn | 273.12m | 24.25bn | 85.00 | 103.94 | 3.31 | 31.85 | 6.09 | 8.97 | 8.97 | 165.54 | 281.96 | 0.3947 | 4.35 | 3.04 | -- | 2.71 | 2.64 | 3.08 | 2.90 | 82.11 | 85.46 | 6.86 | 6.36 | 4.33 | 6.63 | 0.2962 | 0.00 | 28.07 | 29.16 | 155.17 | -- | -13.74 | -- |
Data as of Mar 04 2026. Currency figures normalised to Stella Pharma Corp's reporting currency: Japanese Yen JPY
0.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Amova Asset Management Co., Ltd.as of 14 Nov 2025 | 65.50k | 0.19% |
| Simplex Asset Management Co., Ltd.as of 05 Feb 2026 | 45.20k | 0.13% |
Data from 31 Dec 2025 - 19 Feb 2026Source: FactSet Research Systems Inc.
